BR112012003064B8 - anticorpo ou fragmento de ligação de antígeno do mesmo, combinação que os compreende, método de detecção de infecção por rsv, moléculas de ácido nucléico, e método de produção de um anticorpo ou fragmento de ligação de antígeno do mesmo - Google Patents

anticorpo ou fragmento de ligação de antígeno do mesmo, combinação que os compreende, método de detecção de infecção por rsv, moléculas de ácido nucléico, e método de produção de um anticorpo ou fragmento de ligação de antígeno do mesmo

Info

Publication number
BR112012003064B8
BR112012003064B8 BR112012003064A BR112012003064A BR112012003064B8 BR 112012003064 B8 BR112012003064 B8 BR 112012003064B8 BR 112012003064 A BR112012003064 A BR 112012003064A BR 112012003064 A BR112012003064 A BR 112012003064A BR 112012003064 B8 BR112012003064 B8 BR 112012003064B8
Authority
BR
Brazil
Prior art keywords
antigen
antibody
binding fragment
producing
nucleic acid
Prior art date
Application number
BR112012003064A
Other languages
English (en)
Portuguese (pt)
Other versions
BR112012003064A2 (pt
BR112012003064B1 (pt
Inventor
Keogh Elissa
Pascual Gabriel
Wadia Jehangir
Anthony Williamson Robert
Original Assignee
Crucell Holland Bv
Janssen Vaccines & Prevention Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Crucell Holland Bv, Janssen Vaccines & Prevention Bv filed Critical Crucell Holland Bv
Publication of BR112012003064A2 publication Critical patent/BR112012003064A2/pt
Publication of BR112012003064B1 publication Critical patent/BR112012003064B1/pt
Publication of BR112012003064B8 publication Critical patent/BR112012003064B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1027—Paramyxoviridae, e.g. respiratory syncytial virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A61K49/16—Antibodies; Immunoglobulins; Fragments thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • C12N15/68—Stabilisation of the vector
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
BR112012003064A 2009-08-13 2010-08-13 anticorpo ou fragmento de ligação de antígeno do mesmo, combinação que os compreende, método de detecção de infecção por rsv, moléculas de ácido nucléico, e método de produção de um anticorpo ou fragmento de ligação de antígeno do mesmo BR112012003064B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US27439509P 2009-08-13 2009-08-13
US61/274,395 2009-08-13
PCT/US2010/045549 WO2011020079A1 (en) 2009-08-13 2010-08-13 Antibodies against human respiratory syncytial virus (rsv) and methods of use

Publications (3)

Publication Number Publication Date
BR112012003064A2 BR112012003064A2 (pt) 2017-11-14
BR112012003064B1 BR112012003064B1 (pt) 2021-03-16
BR112012003064B8 true BR112012003064B8 (pt) 2021-05-25

Family

ID=43014487

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012003064A BR112012003064B8 (pt) 2009-08-13 2010-08-13 anticorpo ou fragmento de ligação de antígeno do mesmo, combinação que os compreende, método de detecção de infecção por rsv, moléculas de ácido nucléico, e método de produção de um anticorpo ou fragmento de ligação de antígeno do mesmo

Country Status (18)

Country Link
US (2) US8568719B2 (enExample)
EP (1) EP2464664B1 (enExample)
JP (1) JP5762408B2 (enExample)
KR (1) KR101778317B1 (enExample)
CN (1) CN102656189B (enExample)
BR (1) BR112012003064B8 (enExample)
CA (1) CA2770737C (enExample)
DK (1) DK2464664T3 (enExample)
EA (1) EA023179B1 (enExample)
ES (1) ES2553440T3 (enExample)
IL (1) IL217977A (enExample)
IN (1) IN2012DN01328A (enExample)
MX (1) MX2012001882A (enExample)
NZ (1) NZ597996A (enExample)
PL (1) PL2464664T3 (enExample)
SG (1) SG178335A1 (enExample)
WO (1) WO2011020079A1 (enExample)
ZA (1) ZA201201007B (enExample)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2464664T3 (da) 2009-08-13 2016-01-18 Crucell Holland Bv Antistoffer mod humant respiratorisk syncytialvirus (rsv) og fremgangsmåder til anvendelse deraf
BR112012031638B1 (pt) * 2010-07-09 2021-01-12 Janssen Vaccines & Prevention B.V. anticorpo anti-rsv ou fragmento de ligação de antígeno do mesmo, anticorpo multivalente, composição farmacêutica, uso de anticorpo ou fragmento de ligação de antígeno, método de detectar infecção por rsv, e, ácido nucleico isolado
US8956859B1 (en) 2010-08-13 2015-02-17 Aviex Technologies Llc Compositions and methods for determining successful immunization by one or more vaccines
HUE053545T2 (hu) 2011-05-17 2021-07-28 Univ Rockefeller Humán immundeficiencia vírus semlegesítõ antitestek és eljárások alkalmazásukra
JP2014518080A (ja) * 2011-06-27 2014-07-28 バルネバ 細胞のスクリーニング方法
WO2013006544A1 (en) * 2011-07-06 2013-01-10 Medimmune, Llc Methods for making multimeric polypeptides
US20130165638A1 (en) * 2011-12-27 2013-06-27 Development Center For Biotechnology Light chain-bridged bispecific antibody
CN104159925B (zh) * 2012-03-13 2018-04-24 乌得勒支大学控股有限公司 双特异性接头
NZ630920A (en) 2012-03-20 2017-01-27 Humabs Biomed Sa Antibodies that neutralize rsv, mpv and pvm and uses thereof
CN104662044B (zh) 2012-08-24 2018-10-30 加利福尼亚大学董事会 用于治疗ror1癌症并抑制转移的抗体和疫苗
CN103048459B (zh) * 2012-12-05 2014-08-20 中国科学院武汉病毒研究所 检测呼吸道合胞病毒的免疫检测试剂
EP2968520B1 (en) 2013-03-14 2021-05-12 MacroGenics, Inc. Bispecific molecules that are immunoreactive with immune effector cells that express an activating receptor
TWI659968B (zh) 2013-03-14 2019-05-21 再生元醫藥公司 針對呼吸道融合病毒ｆ蛋白質的人類抗體及其使用方法
CN105188745B (zh) 2013-04-25 2019-10-18 扬森疫苗与预防公司 稳定化的可溶性融合前rsv f多肽
CN105408348B (zh) 2013-06-17 2021-07-06 扬森疫苗与预防公司 稳定化的可溶性融合前rsv f多肽
DK3012633T3 (en) * 2013-06-21 2018-08-13 Alfresa Pharma Corp Immunochromatography device for detection of RSV
US10047145B2 (en) 2013-07-24 2018-08-14 Humabs Biomed Sa Antibodies that potently neutralize RSV and uses thereof
MX380902B (es) * 2013-11-15 2025-03-12 Genentech Inc Métodos para la inactivación viral usando detergentes ecológico.
CN103911389A (zh) * 2014-04-09 2014-07-09 南昌大学 一种检测人呼吸道合胞病毒抗体的g和f蛋白的制备方法
SG11201610446XA (en) 2014-06-26 2017-01-27 Janssen Vaccines & Prevention Bv Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau
ZA201608812B (en) 2014-06-26 2019-08-28 Janssen Vaccines & Prevention Bv Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau
CN105319373B (zh) * 2014-08-18 2017-01-18 董俊 基于磁性分离和量子点标记的人呼吸道合胞病毒快速检测方法和试剂盒
SG11201702544WA (en) 2014-09-29 2017-04-27 Univ Duke Bispecific molecules comprising an hiv-1 envelope targeting arm
WO2016055656A1 (en) * 2014-10-10 2016-04-14 Ablynx N.V. Methods of treating rsv infections
JP2018519333A (ja) * 2015-07-02 2018-07-19 スプリング バンク ファーマシューティカルズ，インコーポレイテッド ウイルス感染の治療のための組成物および方法
CA2991002C (en) 2015-07-07 2023-11-28 Janssen Vaccines & Prevention B.V. Vaccine against rsv
KR20180026734A (ko) 2015-07-07 2018-03-13 얀센 백신스 앤드 프리벤션 비.브이. 안정화된 가용성 융합-전 rsv f 폴리펩티드
JO3555B1 (ar) 2015-10-29 2020-07-05 Merck Sharp & Dohme جسم مضاد يبطل فعالية فيروس الالتهاب الرئوي البشري
CN106496324B (zh) * 2015-11-30 2020-01-14 天津昊免生物技术有限公司 一种抗呼吸道合胞病毒的全人源抗体
CN109232737A (zh) * 2016-03-01 2019-01-18 苏州博泰神州生物技术有限公司 一种针对rsv粘附g蛋白表面抗原的全人源单克隆抗体
CN105753981B (zh) * 2016-03-08 2019-10-08 湖北工业大学 抗人呼吸道合胞病毒n蛋白抗体及应用该抗体的免疫层析试剂盒
US10729757B2 (en) 2016-04-05 2020-08-04 Janssen Vaccines & Prevention B.V. Vaccine against RSV
CN116063551A (zh) 2016-04-05 2023-05-05 扬森疫苗与预防公司 稳定化的可溶性融合前rsv f蛋白
CA3023922C (en) * 2016-05-10 2023-04-18 Georgia State University Research Foundation, Inc. Heterocyclic derivatives for the treatment of rsv
BR112018074483A2 (pt) 2016-05-30 2019-03-19 Janssen Vaccines & Prevention B.V. proteínas f do rsv pré-fusão estabilizadas
KR20240113990A (ko) 2016-06-27 2024-07-23 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 암 치료 조합
AU2017345759B2 (en) * 2016-10-21 2024-06-20 Adimab, Llc Anti-respiratory syncytial virus antibodies, and methods of their generation and use
WO2018150029A1 (en) * 2017-02-17 2018-08-23 Institut Pasteur Generation of monoclonal antibodies targeting respiratory syncytial virus (rsv) using regulatory b cells from newborns (nbregs)
AU2018267971A1 (en) 2017-05-17 2019-11-07 Janssen Vaccines & Prevention B.V. Methods and compositions for inducing protective immunity against RSV infection
JP2020533367A (ja) 2017-09-15 2020-11-19 ヤンセン ファッシンズ アンド プリベンション ベーフェーＪａｎｓｓｅｎ Ｖａｃｃｉｎｅｓ ＆ Ｐｒｅｖｅｎｔｉｏｎ Ｂ．Ｖ． Ｒｓｖに対する免疫の安全な誘導方法
CA3117275A1 (en) 2018-11-13 2020-05-22 Janssen Vaccines & Prevention B.V. Stabilized pre-fusion rsv f proteins
WO2020124846A1 (zh) * 2018-12-18 2020-06-25 珠海泰诺麦博生物技术有限公司 抗呼吸道合胞病毒的中和抗体及其应用
CL2018003869A1 (es) * 2018-12-28 2021-01-15 Univ Pontificia Catolica Chile Anticuerpos monoclonales específicos para la proteína quimérica l del virus de la parainfluenza humana (piv), secuencias nucleotídicas; método y kit de diagnóstico de infección producida por piv
US20220273787A1 (en) 2019-05-15 2022-09-01 Janssen Vaccines & Prevention B.V. Co-administration of seasonal influenza vaccine and an adenovirus based respiratory syncytial virus vaccine
AU2020275910A1 (en) 2019-05-15 2021-11-04 Janssen Vaccines & Prevention B.V. Prophylactic treatment of respiratory syncytial virus infection with an adenovirus based vaccine
US20220308055A1 (en) * 2019-08-27 2022-09-29 University Of Central Florida Research Foundation, Inc. Method and device for pathogen or antibody detection using unmodified signaling substances with or without unlabeled detection reagents
CN111166881B (zh) * 2020-01-06 2023-03-24 国药中生生物技术研究院有限公司 一种重组呼吸道合胞病毒多表位嵌合疫苗及其制备方法和应用
CN115461076A (zh) 2020-04-02 2022-12-09 扬森疫苗与预防公司 稳定化的疫苗组合物
WO2022002894A1 (en) 2020-06-29 2022-01-06 Janssen Vaccines & Prevention B.V. Vaccine combination against respiratory syncytial virus infection
EP4204806A1 (en) * 2020-08-31 2023-07-05 Genentech, Inc. Methods for producing antibodies
FR3114970B1 (fr) * 2020-10-08 2023-06-30 Univ Tours Combinaison d’anticorps inhalés avec des agents immunomodulateurs pour le traitement ou la prévention d’inféctions respiratoires
WO2022127793A1 (zh) * 2020-12-18 2022-06-23 珠海泰诺麦博生物技术有限公司 呼吸道合胞病毒特异性结合分子
WO2022175479A1 (en) 2021-02-19 2022-08-25 Janssen Vaccines & Prevention B.V. Vaccine combinations against respiratory syncytial virus strain a and b infections
CN113249333B (zh) * 2021-03-16 2023-06-02 贵州省人民医院 一种分泌抗呼吸道合胞病毒单克隆抗体的杂交瘤细胞株rsvn4c3
WO2022268120A1 (en) * 2021-06-22 2022-12-29 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Anti-rsv antibodies and uses thereof
JP2024531150A (ja) * 2021-08-10 2024-08-29 アイコサバックス， インコーポレイテッド 呼吸器多核体ウイルスに対するウイルス様粒子ワクチン
WO2025104604A1 (en) 2023-11-14 2025-05-22 Janssen Pharmaceuticals, Inc. Anti-respiratory syncytial virus antibodies and uses thereof
CN117964750B (zh) * 2024-02-04 2024-10-25 北京微星生物科技有限公司 一种抗呼吸道合胞病毒的单克隆抗体及其应用
CN117924472B (zh) * 2024-02-04 2025-02-18 北京微星生物科技有限公司 针对呼吸道合胞病毒的抗体

Family Cites Families (145)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444887A (en) 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
US4391904A (en) * 1979-12-26 1983-07-05 Syva Company Test strip kits in immunoassays and compositions therein
US4714681A (en) 1981-07-01 1987-12-22 The Board Of Reagents, The University Of Texas System Cancer Center Quadroma cells and trioma cells and methods for the production of same
US4474893A (en) 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
US4957939A (en) * 1981-07-24 1990-09-18 Schering Aktiengesellschaft Sterile pharmaceutical compositions of gadolinium chelates useful enhancing NMR imaging
US4472509A (en) * 1982-06-07 1984-09-18 Gansow Otto A Metal chelate conjugated monoclonal antibodies
US4716111A (en) * 1982-08-11 1987-12-29 Trustees Of Boston University Process for producing human antibodies
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US5128326A (en) * 1984-12-06 1992-07-07 Biomatrix, Inc. Drug delivery systems based on hyaluronans derivatives thereof and their salts and methods of producing same
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
US4980286A (en) * 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
US4935233A (en) * 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) * 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
SE459008B (sv) 1986-09-04 1989-05-29 Bioinvent Int Ab Saett att framsstaella humana monoklonala antikroppar
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
US4997764A (en) 1987-04-23 1991-03-05 New York University Transformation of human B-lympocytes with Epstein Barr virus and c-myc containing vectors
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
US4880078A (en) 1987-06-29 1989-11-14 Honda Giken Kogyo Kabushiki Kaisha Exhaust muffler
US5336603A (en) 1987-10-02 1994-08-09 Genentech, Inc. CD4 adheson variants
WO1989012624A2 (en) 1988-06-14 1989-12-28 Cetus Corporation Coupling agents and sterically hindered disulfide linked conjugates prepared therefrom
US4925648A (en) 1988-07-29 1990-05-15 Immunomedics, Inc. Detection and treatment of infectious and inflammatory lesions
US5601819A (en) * 1988-08-11 1997-02-11 The General Hospital Corporation Bispecific antibodies for selective immune regulation and for selective immune cell binding
US5223409A (en) * 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
EP0436597B1 (en) 1988-09-02 1997-04-02 Protein Engineering Corporation Generation and selection of recombinant varied binding proteins
SE461985B (sv) 1988-09-13 1990-04-23 Bioinvent Int Ab In vitro immunisering av lymfocytinnehaallande cellpopulationer och materialsats daerfoer
KR900005995A (ko) 1988-10-31 1990-05-07 우메모또 요시마사 변형 인터류킨-2 및 그의 제조방법
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
EP0394827A1 (en) 1989-04-26 1990-10-31 F. Hoffmann-La Roche Ag Chimaeric CD4-immunoglobulin polypeptides
ZA902949B (en) 1989-05-05 1992-02-26 Res Dev Foundation A novel antibody delivery system for biological response modifiers
DE69029036T2 (de) 1989-06-29 1997-05-22 Medarex Inc Bispezifische reagenzien für die aids-therapie
US5112946A (en) 1989-07-06 1992-05-12 Repligen Corporation Modified pf4 compositions and methods of use
NL8902087A (nl) 1989-08-17 1991-03-18 Stichting Tech Wetenschapp Niet-natuurlijk voorkomend pseudorabiesvirus en vaccins die dit bevatten.
US5436146A (en) 1989-09-07 1995-07-25 The Trustees Of Princeton University Helper-free stocks of recombinant adeno-associated virus vectors
WO1991006570A1 (en) 1989-10-25 1991-05-16 The University Of Melbourne HYBRID Fc RECEPTOR MOLECULES
EP0550436A1 (en) * 1989-11-06 1993-07-14 Alkermes Controlled Therapeutics, Inc. Protein microspheres and methods of using them
EP0434879A1 (en) 1989-12-14 1991-07-03 Schering-Plough Method of making factor dependent human B cell lines
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
AU7247191A (en) 1990-01-11 1991-08-05 Molecular Affinities Corporation Production of antibodies using gene libraries
US5780225A (en) * 1990-01-12 1998-07-14 Stratagene Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US5314995A (en) 1990-01-22 1994-05-24 Oncogen Therapeutic interleukin-2-antibody based fusion proteins
CA2078689C (en) 1990-03-20 2003-02-11 Sherie L. Morrison Chimeric antibodies with receptor binding ligands in place of their constant region
US5427908A (en) * 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US5349053A (en) * 1990-06-01 1994-09-20 Protein Design Labs, Inc. Chimeric ligand/immunoglobulin molecules and their uses
GB9015198D0 (en) * 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5698426A (en) 1990-09-28 1997-12-16 Ixsys, Incorporated Surface expression libraries of heteromeric receptors
EP0553235A1 (en) 1990-10-01 1993-08-04 The University Of Connecticut Targeting viruses and cells for selective internalization by cells
EP0553244B8 (en) 1990-10-05 2005-06-08 Celldex Therapeutics, Inc. Targeted immunostimulation with bispecific reagents
ATE160379T1 (de) 1990-10-29 1997-12-15 Chiron Corp Bispezifische antikörper, verfahren zu ihrer herstellung und deren verwendungen
DK0574395T3 (da) 1990-11-09 2002-10-07 Stephen D Gillies Cytokin-immunkonjugater
WO1992009690A2 (en) * 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with altered binding properties
WO1992010591A1 (en) 1990-12-14 1992-06-25 Cell Genesys, Inc. Chimeric chains for receptor-associated signal transduction pathways
EP1471142B1 (en) 1991-04-10 2008-11-19 The Scripps Research Institute Heterodimeric receptor libraries using phagemids
DK0511011T3 (da) * 1991-04-26 1997-03-10 Surface Active Ltd Nye antistoffer og fremgangsmåde til anvendelse heraf
ATE221379T1 (de) 1991-05-01 2002-08-15 Jackson H M Found Military Med Verfahren zur behandlung infektiöser respiratorischer erkrankungen
JPH06510524A (ja) 1991-05-14 1994-11-24 ユニバーシティ オブ コネチカット 免疫原性タンパク質をコードする遺伝子の標的への配達
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
JPH06510278A (ja) 1991-06-05 1994-11-17 ユニバーシティ オブ コネチカット 分泌タンパク質をコードする遺伝子の標的への配達
CA2110799A1 (en) 1991-06-14 1992-12-23 Arnold H. Horwitz Microbially-produced antibody fragments and their conjugates
US5844095A (en) 1991-06-27 1998-12-01 Bristol-Myers Squibb Company CTLA4 Ig fusion proteins
US6136310A (en) 1991-07-25 2000-10-24 Idec Pharmaceuticals Corporation Recombinant anti-CD4 antibodies for human therapy
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5262522A (en) 1991-11-22 1993-11-16 Immunex Corporation Receptor for oncostatin M and leukemia inhibitory factor
WO1993011236A1 (en) 1991-12-02 1993-06-10 Medical Research Council Production of anti-self antibodies from antibody segment repertoires and displayed on phage
US5824307A (en) 1991-12-23 1998-10-20 Medimmune, Inc. Human-murine chimeric antibodies against respiratory syncytial virus
AU3434393A (en) 1992-01-17 1993-08-03 Regents Of The University Of Michigan, The Targeted virus
US5622929A (en) * 1992-01-23 1997-04-22 Bristol-Myers Squibb Company Thioether conjugates
US5667988A (en) 1992-01-27 1997-09-16 The Scripps Research Institute Methods for producing antibody libraries using universal or randomized immunoglobulin light chains
AU3737893A (en) 1992-03-05 1993-10-05 Board Of Regents, The University Of Texas System Diagnostic and/or therapeutic agents, targeted to neovascular endothelial cells
US5912015A (en) * 1992-03-12 1999-06-15 Alkermes Controlled Therapeutics, Inc. Modulated release from biocompatible polymers
US5733743A (en) * 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US5447851B1 (en) 1992-04-02 1999-07-06 Univ Texas System Board Of Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells
EP0633943A4 (en) 1992-04-03 1997-05-02 Alexander T Young GENTHERAPY USING TARGETED VIRAL VECTORS.
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
ES2191016T3 (es) 1992-09-16 2003-09-01 Scripps Research Inst Anticuerpos monoclonales neutralizantes humanos para el virus respiratorio sincitial.
US6685942B1 (en) 1993-12-10 2004-02-03 The Scripps Research Institute Human neutralizing monoclonal antibodies to respiratory syncytial virus
ES2157225T3 (es) 1992-10-09 2001-08-16 Advanced Tissue Sciences Inc Celulas hepaticas de reserva.
JPH08503855A (ja) 1992-12-03 1996-04-30 ジェンザイム・コーポレイション 嚢胞性線維症に対する遺伝子治療
US5359681A (en) 1993-01-11 1994-10-25 University Of Washington Fiber optic sensor and methods and apparatus relating thereto
US5934272A (en) 1993-01-29 1999-08-10 Aradigm Corporation Device and method of creating aerosolized mist of respiratory drug
EP0619323A1 (en) 1993-04-09 1994-10-12 Schering-Plough Human monoclonal antibodies and processes and materials for making such antibodies
US5457035A (en) * 1993-07-23 1995-10-10 Immunex Corporation Cytokine which is a ligand for OX40
AU696293B2 (en) 1993-12-08 1998-09-03 Genzyme Corporation Process for generating specific antibodies
DK0744958T3 (da) 1994-01-31 2003-10-20 Univ Boston Polyklonale antistofbiblioteker
US5834252A (en) * 1995-04-18 1998-11-10 Glaxo Group Limited End-complementary polymerase reaction
US5837458A (en) 1994-02-17 1998-11-17 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
US5516637A (en) 1994-06-10 1996-05-14 Dade International Inc. Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage
GB9415379D0 (en) * 1994-07-29 1994-09-21 Smithkline Beecham Plc Novel compounds
NZ292124A (en) 1994-07-29 1998-10-28 Smithkline Beecham Plc Il-4 antagonist comprising a fusion of a mutant il-4-antibody fragment
WO1996006641A1 (en) 1994-08-29 1996-03-07 Prizm Pharmaceuticals, Inc. Conjugates of vascular endothelial growth factor with targeted agents
US6030613A (en) 1995-01-17 2000-02-29 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
EP1658772A3 (en) 1995-01-17 2007-01-17 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of immunogens
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US6019968A (en) * 1995-04-14 2000-02-01 Inhale Therapeutic Systems, Inc. Dispersible antibody compositions and methods for their preparation and use
DE69637481T2 (de) 1995-04-27 2009-04-09 Amgen Fremont Inc. Aus immunisierten Xenomäusen stammende menschliche Antikörper gegen IL-8
EP0823941A4 (en) 1995-04-28 2001-09-19 Abgenix Inc HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES
US5811524A (en) 1995-06-07 1998-09-22 Idec Pharmaceuticals Corporation Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereof
WO1997007788A2 (en) 1995-08-31 1997-03-06 Alkermes Controlled Therapeutics, Inc. Composition for sustained release of an agent
US5840300A (en) * 1995-09-11 1998-11-24 Trustees Of The University Of Pennsylvania Methods and compositions comprising single chain recombinant antibodies
AU7240096A (en) * 1995-09-18 1997-04-09 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Neutralizing monoclonal antibodies to respiratory syncytial virus
GB9601081D0 (en) 1995-10-06 1996-03-20 Cambridge Antibody Tech Specific binding members for human transforming growth factor beta;materials and methods
US5723125A (en) 1995-12-28 1998-03-03 Tanox Biosystems, Inc. Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide
JP2978435B2 (ja) 1996-01-24 1999-11-15 チッソ株式会社 アクリロキシプロピルシランの製造方法
DK0885002T3 (da) 1996-03-04 2011-08-22 Penn State Res Found Materialer og fremgangsmåder til forøgelse af cellulær internalisering
AU728657B2 (en) 1996-03-18 2001-01-18 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US5855913A (en) * 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery
US5985309A (en) 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
US5874064A (en) * 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
US20020141990A1 (en) 1996-11-01 2002-10-03 Smithkline Beecham Corporation Anti-RSV human monoclonal antibodies
US5842307A (en) 1996-11-15 1998-12-01 May; Kenzel Self-adjusting, automatic spot weed sprayer
ES2301183T3 (es) 1996-12-03 2008-06-16 Amgen Fremont Inc. Anticuerpo completamente humano que se une al receptor del egfr.
ATE287257T1 (de) 1997-01-16 2005-02-15 Massachusetts Inst Technology Zubereitung von partikelhaltigen arzneimitteln zur inhalation
CN100387621C (zh) 1997-04-14 2008-05-14 麦可麦脱股份公司 抗人抗原受体的新的生产方法及其用途
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
US5989463A (en) * 1997-09-24 1999-11-23 Alkermes Controlled Therapeutics, Inc. Methods for fabricating polymer-based controlled release devices
SE512663C2 (sv) 1997-10-23 2000-04-17 Biogram Ab Inkapslingsförfarande för aktiv substans i en bionedbrytbar polymer
CZ121599A3 (cs) 1998-04-09 1999-10-13 Aventis Pharma Deutschland Gmbh Jednořetězcová molekula vázající několik antigenů, způsob její přípravy a léčivo obsahující tuto molekulu
AU747231B2 (en) 1998-06-24 2002-05-09 Alkermes, Inc. Large porous particles emitted from an inhaler
US6472147B1 (en) 1999-05-25 2002-10-29 The Scripps Research Institute Methods for display of heterodimeric proteins on filamentous phage using pVII and pIX, compositions, vectors and combinatorial libraries
US7229619B1 (en) 2000-11-28 2007-06-12 Medimmune, Inc. Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
JP4992068B2 (ja) 2000-01-27 2012-08-08 メディミューン，エルエルシー 超高親和性中和抗体
US20050175986A1 (en) * 2000-05-09 2005-08-11 Smit Kline Beecham Corporation Human monoclonal antibody
US6818216B2 (en) 2000-11-28 2004-11-16 Medimmune, Inc. Anti-RSV antibodies
FR2817875B1 (fr) 2000-12-07 2005-03-18 Technopharm Procede de preparation d'un anticorps monoclonal humain, de fragments de celui-ci ou d'anticorps comprenant de tels fragments, les anticorps ainsi obtenus et leur utilisation
ES2649037T3 (es) * 2000-12-12 2018-01-09 Medimmune, Llc Moléculas con semividas prolongadas, composiciones y usos de las mismas
US8188231B2 (en) 2002-09-27 2012-05-29 Xencor, Inc. Optimized FC variants
US7217797B2 (en) * 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
EP1597280B2 (en) 2003-02-26 2016-08-24 Institute for Research in Biomedicine Monoclonal antibody production by ebv transformation of b cells
US7070786B2 (en) * 2003-06-06 2006-07-04 Centocor, Inc. RSV proteins, antibodies, compositions, methods and uses
JP2007531707A (ja) * 2003-10-15 2007-11-08 ピーディーエル バイオファーマ， インコーポレイテッド ＩＧの重鎖定常領域の位置２５０、３１４および／または４２８の変異誘発によるＦｃ融合タンパク質血清半減期の改変
EP2275448A3 (en) 2003-12-19 2013-02-06 Genentech, Inc. Monovalent antibody fragments useful as therapeutics
WO2005079479A2 (en) 2004-02-17 2005-09-01 Absalus, Inc. Super-humanized antibodies against respiratory syncytial virus
TW200636064A (en) * 2004-10-28 2006-10-16 Centocor Inc Anti-respiratory syncytial virus antibodies, antigens and uses thereof
BRPI0619908A2 (pt) 2005-12-16 2011-10-25 Ribovax Biotechnologies Sa método para imortalização de uma população de células, população de células, população de células oligoclonal ou monoclonal, cultura celular, sobrenadante de uma cultura celular, biclioteca de dnas, uso de uma população de células, cultura celular, sobrenadante ou biblioteca de dnas, kit para identificar e produzir um anticorpo monoclonal, método para produzir uma cultura celular, e método para produzir um anticorpo monoclonal
AU2008224259A1 (en) * 2007-03-06 2008-09-12 Symphogen A/S Recombinant antibodies for treatment of respiratory syncytial virus infections
CN101821289A (zh) * 2007-09-07 2010-09-01 西福根有限公司 重组制造抗rsv抗体的方法
EP2201040A1 (en) 2007-09-24 2010-06-30 Vanderbilt University Monoclonal antibodies to respiratory syncytial virus and uses thereof
DK2464664T3 (da) 2009-08-13 2016-01-18 Crucell Holland Bv Antistoffer mod humant respiratorisk syncytialvirus (rsv) og fremgangsmåder til anvendelse deraf
BR112012031638B1 (pt) * 2010-07-09 2021-01-12 Janssen Vaccines & Prevention B.V. anticorpo anti-rsv ou fragmento de ligação de antígeno do mesmo, anticorpo multivalente, composição farmacêutica, uso de anticorpo ou fragmento de ligação de antígeno, método de detectar infecção por rsv, e, ácido nucleico isolado

Also Published As

Publication number Publication date
BR112012003064A2 (pt) 2017-11-14
US9365638B2 (en) 2016-06-14
NZ597996A (en) 2014-02-28
JP2013501527A (ja) 2013-01-17
CN102656189B (zh) 2014-10-08
US20140044719A1 (en) 2014-02-13
EP2464664B1 (en) 2015-09-23
WO2011020079A1 (en) 2011-02-17
IN2012DN01328A (enExample) 2015-06-05
EP2464664A1 (en) 2012-06-20
CA2770737A1 (en) 2011-02-17
CA2770737C (en) 2020-05-12
US20110076268A1 (en) 2011-03-31
KR20120050480A (ko) 2012-05-18
EA023179B1 (ru) 2016-05-31
HK1172350A1 (zh) 2013-04-19
MX2012001882A (es) 2012-04-11
IL217977A (en) 2016-06-30
JP5762408B2 (ja) 2015-08-12
DK2464664T3 (da) 2016-01-18
ES2553440T3 (es) 2015-12-09
CN102656189A (zh) 2012-09-05
SG178335A1 (en) 2012-03-29
BR112012003064B1 (pt) 2021-03-16
KR101778317B1 (ko) 2017-09-13
US8568719B2 (en) 2013-10-29
EA201200277A1 (ru) 2012-09-28
ZA201201007B (en) 2019-08-28
PL2464664T3 (pl) 2016-02-29
IL217977A0 (en) 2012-03-29
AU2010282312A1 (en) 2012-02-23

Similar Documents

Publication Publication Date Title
BR112012003064B8 (pt) anticorpo ou fragmento de ligação de antígeno do mesmo, combinação que os compreende, método de detecção de infecção por rsv, moléculas de ácido nucléico, e método de produção de um anticorpo ou fragmento de ligação de antígeno do mesmo
EA201291243A1 (ru) Антитела против респираторно-синцитиального вируса (рсв) и способы их применения
EA201190041A1 (ru) Человеческие аутоантитела против альфа-синуклеина
EA201991763A1 (ru) Конъюгаты антитела к ccr7 и лекарственного средства
ECSP12012272A (es) Proteínas que se unen al tnf-?
CL2014001334A1 (es) Una proteina de union, anticuerpos o fragmentos del mismo que se une a her-3; molecula de acido nucleico que la codifica; procedimiento de produccion; composicion farmaceutica que lo comprende ; su uso para tratar enfermedades asociadas a her -3; y metodo de diagnostico de una enfermedad (div. sol. 3748-2006).
PE20071055A1 (es) Anticuerpos anti mn
CY1117302T1 (el) Αντισωματα αντι-mif
GT200800269A (es) Una novedosa virulencia determinada dentro de la glicoproteina estructural e2 del virus clasico de la fiebre porcina
BR112015019066A2 (pt) Anticorpos humanos para proteína f do vírus respiratório sincicial e métodos de uso dos mesmos
UA109633C2 (uk) Антитіло людини проти тканинного фактора
ATE503770T1 (de) Humane monoklonale antikörper gegen hendra- und nipah-viren
EA201490825A8 (ru) Tdp-43-специфически связывающие молекулы
PE20150023A1 (es) Proteinas de union a antigeno st2
ECSP10010322A (es) Anticuerpos contra el virus de la influenza y métodos de uso de los mismos
BRPI0412245A (pt) anticorpos de rg1 e usos destes
BR112012005713A2 (pt) vacinas direcionadas a célula langerhans.
AR067199A1 (es) Proteinas de union a antigenos que se unen a par-2
BR112013021350A2 (pt) anticorpo e antígeno reconhecido de células iniciadoras de tumor e o uso destes
CL2008003784A1 (es) Anticuerpo humanizado anti proteina e2 del virus de la hepatitis c o un fragmento de union; acido nucleico que lo codifica; vector y celula huesped que comprenden dicho acido nucleico; metodo para producir el anticuerpo; composicion farmaceutica que comprende el anticuerpo
RU2011121818A (ru) Способ иммунологического анализа белка cxcl1 человека
BR112015012708A2 (pt) anticorpos para bmp-6
CY1121856T1 (el) Αντισωματα εξουδετερωσης jcv
MX2018001244A (es) Anticuerpos monoclonales especificos para el antigeno p del virus respiratorio sincicial humano (vrsh), producidos y secretados por hibridomas celulares, utiles para la deteccion y el diagnostico de la infeccion causada por vrsh.
BR112022004302A2 (pt) Anticorpos anti-il-27 e usos dos mesmos

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B15K Others concerning applications: alteration of classification

Ipc: C07K 16/10 (2006.01), A61K 39/42 (2006.01), A61P 3

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25D Requested change of name of applicant approved

Owner name: JANSSEN VACCINES AND PREVENTION B.V (NL)

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B25G Requested change of headquarter approved

Owner name: JANSSEN VACCINES AND PREVENTION B.V. (NL)

B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 16/03/2021, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 13/08/2010 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 12A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2683 DE 07-06-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.